This week, we proudly showcased Pirouette’s cutting-edge Naloxone auto-injector, 'REZQGO,' in DC at the prestigious National Institutes of Health (NIH) and Biomedical Advanced Research and Development Authority (BARDA) conference, where innovation meets impact in the fight against the opioid crisis.⚕️

The NIH and BARDA are at the forefront of advancing medical innovation to protect and improve public health. Their collaboration creates a vital platform for breakthrough technologies like REZQGO, our Naloxone auto-injector which we are aiming to offer as a new weapon against the devastating opioid overdose crisis.

The conference gave us an incredible platform to present our patented technology to influential stakeholders, including leaders from the NIH, BARDA, the Military/Department of Defense, and academia. We also engaged with drug developers eager to explore opportunities integrating  their medications with our device, for opioid overdoses and a wide array of medical countermeasures. These connections are essential as we expand the applications of our auto-injector technology.

We are grateful for the support of NIH and BARDA, which helps us move closer to making critical medications accessible, reliable, and easy to use for those who need them most.

🚨Our investment round is now 95% full. If you’re considering investing or increasing your stake, there is only a limited window to do so. Together, we’re transforming the future of drug delivery.

💸 Invest or increase your investment TODAY!

Here’s to breaking barriers and saving lives,

Conor